Form 4: Traws Pharma Director Mary Teresa Shoemaker Granted 23,000 Stock Options

Traws Pharma, Inc. Director Mary Teresa Shoemaker has been granted 23,000 stock options with an exercise price of $1.65 per share, vesting on the first anniversary of the grant date.

Summary

• Mary Teresa Shoemaker, a Director of Traws Pharma, Inc. (TRAW), was granted 23,000 stock options.
• The options have an exercise price of $1.65 per share.
• The grant date for these options was June 19, 2025.
• These options will vest 100% on June 19, 2026, which is the first anniversary of the grant date.
• The options have an expiration date of June 19, 2035.
• Following this transaction, Mary Teresa Shoemaker beneficially owns 23,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The document reports a routine compensation event (stock option grant) to a director, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications or unexpected events reported.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases.
• It represents a form of long-term incentive compensation for the director's continued service and contribution to the company.

Future Outlook

The stock options are set to vest 100% on June 19, 2026, indicating a future milestone for the director's equity compensation.

Industry Context

The granting of stock options to directors is a common practice across various industries, including pharmaceuticals, as a means of executive and board compensation, aligning leadership incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• Granting stock options to directors is a standard component of compensation packages in publicly traded companies, including those in the pharmaceutical sector like Traws Pharma, Inc.
• The vesting schedule of 100% on the first anniversary of the grant date is a common approach for director equity awards, aiming to retain talent and incentivize long-term commitment.

Related Party Transactions

• The grant of stock options to Mary Teresa Shoemaker, a Director, constitutes a transaction with a related party, which is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on June 19, 2026, at which point Mary Teresa Shoemaker will be able to exercise them.

Key Dates

Keywords

Traws Pharma, TRAW, SEC Form 4, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant